The Impact of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorder Beyond Infection Risk
暂无分享,去创建一个
[1] Russell S. Peak,et al. Part 2: , 2020, Journal of Neural Transmission.
[2] H. Hartung,et al. Targeting B Cells to Modify MS, NMOSD, and MOGAD , 2020, Neurology: Neuroimmunology & Neuroinflammation.
[3] H. Hartung,et al. Targeting B Cells to Modify MS, NMOSD, and MOGAD , 2020, Neurology: Neuroimmunology & Neuroinflammation.
[4] C. Louapre,et al. COVID-19 infection in NMO/SD patients: a French survey , 2020, Journal of Neurology.
[5] C. Louapre,et al. Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? , 2020, Multiple Sclerosis and Related Disorders.
[6] L. Cui,et al. Prediction of long-term disability in Chinese patients with multiple sclerosis: A prospective cohort study. , 2020, Multiple sclerosis and related disorders.
[7] E. Ciampi,et al. COVID-19 in MS and NMOSD: A multicentric online national survey in Chile , 2020, Multiple Sclerosis and Related Disorders.
[8] Sharon J Peacock,et al. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.
[9] Y. Bao,et al. Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic , 2020, JAMA network open.
[10] M. Han,et al. The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study. , 2020, Multiple sclerosis and related disorders.
[11] F. Shi,et al. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders , 2020, Neurology: Neuroimmunology & Neuroinflammation.
[12] A. Serra,et al. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic , 2020, Multiple Sclerosis and Related Disorders.
[13] M. Sahraian,et al. Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran , 2020, Multiple Sclerosis and Related Disorders.
[14] J. Pačes,et al. COVID-19 and the immune system. , 2020, Physiological research.
[15] R. Baric,et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.
[16] J. Imitola,et al. Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis optica spectrum disorder. , 2020, Multiple Sclerosis and Related Disorders.
[17] Cezmi A Akdis,et al. Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19 , 2020, Allergy.
[18] R. Kream,et al. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development , 2020, Medical science monitor : international medical journal of experimental and clinical research.
[19] Zacharias E. Andreadakis,et al. The COVID-19 vaccine development landscape , 2020, Nature Reviews Drug Discovery.
[20] Xuetao Cao. COVID-19: immunopathology and its implications for therapy , 2020, Nature Reviews Immunology.
[21] F. Claas,et al. HLA association in MOG-IgG– and AQP4-IgG–related disorders of the CNS in the Dutch population , 2020, Neurology: Neuroimmunology & Neuroinflammation.
[22] L. Cui,et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders , 2020, Neurology: Neuroimmunology & Neuroinflammation.
[23] T. Palaga,et al. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. , 2020, Asian Pacific journal of allergy and immunology.
[24] G. Leung,et al. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study , 2020, The Lancet.
[25] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[26] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[27] Jacqueline Palace,et al. International multicenter examination of MOG antibody assays , 2020, Neurology: Neuroimmunology & Neuroinflammation.
[28] A. Espiritu,et al. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. , 2019, Multiple sclerosis and related disorders.
[29] K. Chu,et al. Pneumonia in hospitalized neurologic patients: trends in pathogen distribution and antibiotic susceptibility , 2019, Antimicrobial resistance and infection control.
[30] Chun-juan Wang,et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder , 2018, Journal of the Neurological Sciences.
[31] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[32] H. Ren,et al. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study , 2016, Journal of the Neurological Sciences.
[33] F. Paul,et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin , 2016, Journal of Neuroinflammation.
[34] Y. Itoyama,et al. Impact of the Great East Japan Earthquake in 2011 on MS and NMOSD: a study in Sendai, Japan , 2016, Journal of Neurology, Neurosurgery & Psychiatry.
[35] C. Tan. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2016, Neurology.
[36] A. Traboulsee,et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.
[37] Zhengqi Lu,et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders , 2014, Neurology.
[38] Jacqueline A Palace,et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. , 2014, JAMA neurology.
[39] K. Fujihara,et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders , 2014, Neurology.
[40] S. Yaghi,et al. The effect of war stress on multiple sclerosis exacerbations and radiological disease activity , 2010, Journal of the Neurological Sciences.
[41] Ariel Miller,et al. Impact of exposure to war stress on exacerbations of multiple sclerosis , 2008, Annals of neurology.
[42] David C. Mohr,et al. A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis , 2006, Brain, Behavior, and Immunity.
[43] T. Patterson,et al. Severely threatening events and marked life difficulties preceding onset or exacerbation of multiple sclerosis. , 1989, Journal of neurology, neurosurgery, and psychiatry.
[44] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[45] R. C. Macridis. A review , 1963 .
[46] E. Palmquist. Report from Iran. , 1955, Pediatrics.
[47] L. Cui,et al. Acute epileptic seizures in myelin oligodendrocyte glycoprotein encephalomyelitis and neuromyelitis optica spectrum disorder: A comparative cohort study. , 2019, Multiple sclerosis and related disorders.
[48] H. Hakimzadeh,et al. Part 1 , 2011 .
[49] V. Preedy,et al. Prospective Cohort Study , 2010 .
[50] J. Manson,et al. Prospective Study of , 2007 .